Stocks and Investing Stocks and Investing
Wed, November 15, 2023
Tue, November 14, 2023

Raghuram Selvaraju Maintained (ACRS) at Strong Buy with Decreased Target to $9 on, Nov 14th, 2023


Published on 2024-10-28 07:34:48 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy with Decreased Target from $43 to $9 on, Nov 14th, 2023.

Raghuram has made no other calls on ACRS in the last 4 months.



There are 3 other peers that have a rating on ACRS. Out of the 3 peers that are also analyzing ACRS, 2 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Alex Thompson of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $2 on, Monday, November 13th, 2023
  • Tim Lugo of "William Blair" Downgraded from Buy to Hold on, Monday, November 13th, 2023


This is the rating of the analyst that currently disagrees with Raghuram


  • Gavin Clark-Gartner of "Evercore ISI Group" Initiated at Buy and Held Target at $22 on, Tuesday, October 3rd, 2023
Contributing Sources